Wednesday, 21 Nov 2018

Biologic/Novel Rx

Datesort ascending Type Title Save
07 Nov 2017 Social RT @CCalabreseDO: Effect of live HZ vaccine in MTX-IR w/RA getting tofa or ADA +/- MTX: well-tolerated, higher HZ rates in tofa+MTX #2393 #…
07 Nov 2017 Social RT @japaoli19: Benefits of IL6 blockade on insulin resistance in RA #1400 #ACR17 @RheumNow https://t.co/tYFYRnRlof
07 Nov 2017 Social RT @CCalabreseDO: R. Fleischmann regarding biosimilars, “there are not savings for the patient” @RheumNow #ACR17 https://t.co/qdwVqsV3Zq
06 Nov 2017 Social RT @regeneron: In rheumatoid #arthritis, chronically elevated IL-6 levels may drive inflammation & joint destruction. #ACR17 https://t.co/h…
06 Nov 2017 Social RT @_connectedcare: Here’s a list of other biologics being trialed in GCA. An exciting time #acr17 @RheumNow https://t.co/nqNtRHSSni
06 Nov 2017 Social RT @LCalabreseDO: Stefan Rose-John knocks down vitals of cis/trans IL6 signaling at #ACR17- Rheum’s need 2 know! @HealioRheum @Actemra @iKe…
05 Nov 2017 Social RT @HealioRheum: Maternal #biologic use did not increase risk for opportunistic infections in #newborns https://t.co/1Iaj1awDK0 #ACR17 http…
05 Nov 2017 Social RT @_connectedcare: Impressive result for Mepolizumab in EGPA #ACR17 @rheumnow https://t.co/YhqvGLwpMu
05 Nov 2017 Social RT @WIRheum: Great debate: patient and provider preferences around biosimilar use from @RheumNow survey #ACR17 https://t.co/MgBXZ9gyeV
05 Nov 2017 Social RT @WIRheum: Great Debate "No evidence" that biosimilar is non-inferior to originator #ACR17 @RheumNow https://t.co/mHyoGF4ULS
05 Nov 2017 Social Year in Review. Dan Solomon reviews and shows no cancer risk with Biologics. #ACR17 https://t.co/wra8tf1viY
05 Nov 2017 News BMS Featured Presentations from ACR 2017
04 Nov 2017 Social RT @_connectedcare: Reminder slide re Biologics & which diseases they work in #ACR17 https://t.co/4ClkyiqdkO
23 Oct 2017 News Biosimilars Projected to Yield $54 Billion in Savings
23 Oct 2017 Social H Zoster inactive vaccine Shingrix FDA approved for use in adults >50yrs, >90% protection, 2 shots 2 mos apart https://t.co/c5uT04AtOw
20 Oct 2017 Social RT @emartinmola: High ‘nocebo’ effect observed when patients knowingly switch to a biosimilar https://t.co/IenWgRZUQL
18 Oct 2017 Social In a transition/switch study, SB2(infliximab biosimilar) was equal in efficacy & safety to ref infliximab for 78 wks https://t.co/qSnIoJuTG9
18 Oct 2017 Social Janssen halts anti-IL6 sirukumab development citing FDA rejection and need for more clinical data. https://t.co/3SLehEbLO0
16 Oct 2017 Social RT @USMerckProducts: Biosimilars are a new development in biologic medicines. To learn more, visit: https://t.co/mzo2DfBqKU https://t.co/TT…
11 Oct 2017 Social Multicenter study of135 JIA pts who stopped biologic - 76% flared; more if W/D tried before 2 years of remission. https://t.co/Fn0YXPUGkO